ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib, which we take as illustrative example, was launched in 2001 as the first targeted inhibitor of the spontaneously active tyrosine kinase BRC-ABL produced in myeloblasts after the Philadelphia chromosome mutation causing chronic myelogenous leukemia (CML).